ResMed Inc. (RMD) Shares Sold by Halsey Associates Inc. CT

Halsey Associates Inc. CT cut its position in ResMed Inc. (NYSE:RMD) by 1.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 160,212 shares of the medical equipment provider’s stock after selling 3,142 shares during the period. ResMed makes up about 3.3% of Halsey Associates Inc. CT’s investment portfolio, making the stock its 8th largest holding. Halsey Associates Inc. CT owned about 0.11% of ResMed worth $18,479,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. BlackRock Inc. raised its holdings in ResMed by 2.1% in the third quarter. BlackRock Inc. now owns 11,180,412 shares of the medical equipment provider’s stock worth $1,289,550,000 after buying an additional 226,612 shares during the last quarter. Baillie Gifford & Co. raised its holdings in ResMed by 0.3% in the third quarter. Baillie Gifford & Co. now owns 4,841,478 shares of the medical equipment provider’s stock worth $558,416,000 after buying an additional 14,627 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in ResMed by 0.7% in the third quarter. Bank of New York Mellon Corp now owns 1,632,771 shares of the medical equipment provider’s stock worth $188,324,000 after buying an additional 11,927 shares during the last quarter. Deutsche Bank AG raised its holdings in ResMed by 323.1% in the third quarter. Deutsche Bank AG now owns 1,367,475 shares of the medical equipment provider’s stock worth $157,721,000 after buying an additional 1,044,295 shares during the last quarter. Finally, Morgan Stanley raised its holdings in ResMed by 30.2% in the second quarter. Morgan Stanley now owns 966,736 shares of the medical equipment provider’s stock worth $100,135,000 after buying an additional 223,963 shares during the last quarter. 64.84% of the stock is owned by institutional investors and hedge funds.

In other news, insider James Hollingshead sold 600 shares of ResMed stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $112.09, for a total value of $67,254.00. Following the completion of the sale, the insider now directly owns 83,689 shares in the company, valued at $9,380,700.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brett Sandercock sold 2,000 shares of ResMed stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $114.30, for a total transaction of $228,600.00. Following the completion of the sale, the chief financial officer now owns 73,232 shares of the company’s stock, valued at $8,370,417.60. The disclosure for this sale can be found here. Insiders sold 30,720 shares of company stock valued at $3,290,532 over the last quarter. Company insiders own 1.24% of the company’s stock.

Several research analysts have issued reports on the stock. BMO Capital Markets raised shares of ResMed from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $109.00 to $127.00 in a report on Monday, December 10th. Credit Suisse Group raised shares of ResMed from a “neutral” rating to an “outperform” rating in a report on Friday, October 26th. One analyst has rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $123.50.

Shares of RMD stock opened at $112.93 on Friday. ResMed Inc. has a 52 week low of $84.37 and a 52 week high of $116.64. The company has a market capitalization of $16.09 billion, a PE ratio of 31.99, a P/E/G ratio of 2.88 and a beta of 1.01. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.58 and a quick ratio of 1.91.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Thursday, October 25th. The medical equipment provider reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.80 by $0.01. ResMed had a net margin of 13.94% and a return on equity of 26.29%. The firm had revenue of $588.28 million during the quarter, compared to analyst estimates of $576.66 million. Equities research analysts anticipate that ResMed Inc. will post 3.69 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, December 13th. Stockholders of record on Thursday, November 8th were paid a $0.37 dividend. The ex-dividend date of this dividend was Wednesday, November 7th. This represents a $1.48 dividend on an annualized basis and a dividend yield of 1.31%. ResMed’s dividend payout ratio is presently 41.93%.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/12/16/resmed-inc-rmd-shares-sold-by-halsey-associates-inc-ct.html.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit